Bibliography 1. Troyanov S, et al. J
Am Soc Nephrol. 2005;16:1061–8. (Level 4) 2. Agarwal SK, et al. Nephron. 1993;63:168–71. (Level 4) 3. Frassinetti Castelo Branco Camurça Fernandes P, et al. J Nephrol. 2005;18:711–20. (Level 4) 4. Cattran DC, et al. Kidney Int. 1999;56:2220–6. (Level 2) 5. Lee HY, et al. Clin Nephrol. 1995;43:375–81. (Level 4) 6. Walker RG, et al. Nephron. 1990;54:117–21. (Level 2) 7. Ponticelli C, et al. Kidney Int. 1993;43:1377–84. (Level 2) 8. Braun N, et al. Cochrane Database Syst Rev. 2008;3:CD003233. (Level 1) 9. Senthil Nayagam L, et al. Nephrol Dial Transplant. 2008;23:1926–30. (Level 2) 10. Westhoff TH, et al. Clin Nephrol. 2006;65:393–400. (Level 4) 11. Cattran DC, et al. Clin Nephrol. 2004;62:405–11. (Level 4) 12. Martinelli R, et al. Braz J Med Biol Res. 2004;37:1365–72. Y-27632 order (Level 3) 13. Heering P, et al. Am J Kidney Dis. 2004;43:10–8. (Level 2) Is LDL apheresis recommended for reducing urinary protein levels in patients with FSGS? LDL apheresis is expected not only to improve dyslipidemia,
but also to reduce proteinuria and preserve renal function via immunomodulation in refractory nephrotic syndrome. Several nonrandomized studies learn more using variable schedules of LDL apheresis in patients with steroid-resistant FSGS have demonstrated some benefits in terms of reducing proteinuria and improving the serum albumin concentration. The health insurance system in Japan supports the use of LDL apheresis 12 times within 3 months for refractory nephrotic syndrome with a high LDL PtdIns(3,4)P2 cholesterol level.
Bibliography 1. Tojo K, et al. Jpn J Nephrol. 1988;30:1153–60. (Level 5) 2. Muso E, et al. Nephron. 2001;89:408–15. (Level 4) 3. Hattori M, et al. Am J Kidney Dis. 2003;42:1121–30. (Level 5) 4. Muso E, et al. Clin Nephrol. 2007;67:341–4. (Level 4) Chapter 12: Autosomal-dominant polycystic kidney disease (ADPKD) Is anti-hypertensive treatment recommended as a means of slowing the deterioration of renal function in hypertensive patients with ADPKD? Hypertension in ADPKD is frequent and develops from youth in contrast to essential hypertension. In addition, it is often recognized when the renal function is normal and the cysts are still small. Anti-hypertensive treatment is generally performed. Although the evidence related to recommended anti-hypertensive agents and the target blood pressure is inconclusive, antihypertensive treatment is HMPL-504 cell line thought to slow the deterioration of renal function in hypertensive patients with ADPKD. Bibliography 1. Cadnapaphornchai MA, et al. Clin J Am Soc Nephrol. 2009;4:820–9. (Level 2) 2. Sarnak MJ, et al. Ann Intern Med. 2005;142:342–51. (Level 2) 3. Schrier RW, et al. Kidney Int. 2003;63:678–85. (Level 4) 4. Jafar TH, et al. Kidney Int. 2005;67:265–71. (Level 1) 5. Maschio G, et al. N Engl J Med. 1996;334:939–45. (Level 2) 6. van Dijk MA, et al. Nephrol Dial Transplant. 2003;18:2314–20.